

H/M
HB
9/27/01

Attorney Docket No. P31853C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Buckingham, *et al.* August 24, 2001
Serial No.: Not Assigned Group Art Unit No.: Not Assigned
Filed: Herewith Examiner: Not Assigned
For: TREATMENT OF DIABETES WITH THIAZOLIDINEDIONE,
INSULIN SECRETAGOGUE AND DIGUANIDE

PRELIMINARY AMENDMENT

Preliminary to the examination of this application, Applicants respectfully request amendment of the above-identified application as follows:

In the Specification:

Kindly add the Abstract enclosed herewith on a separate sheet, at the end.

In the Claims:

Please amend claims 4-12, 16, 18-20 and 22 as follows:

4. (Amended) A method according to claim 1, wherein the insulin sensitiser is 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (Compound I).

5. (Amended) A method according to claim 4, which comprises the administration of 2 to 12 mg of Compound (I).

6. (Amended) A method according to claim 5, which comprises the administration of 2 to 4, 4 to 8 or 8 to 12 mg of Compound (I).

7. (Amended) A method according to claim 6, which comprises the administration of 2 to 4mg of Compound (I).

8. (Amended) A method according to claim 6, which comprises the method the administration of 4 to 8mg of Compound (I).